TuHURA Biosciences (HURA) 10-Q14 May 242024 Q3 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Mar. 31, 2024	May 13, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Trading Symbol	KTRA
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity Registrant Name	Kintara Therapeutics, Inc.
Entity Central Index Key	0001498382
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		55,304,613,000
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Incorporation, State or Country Code	NV
Entity File Number	001-37823
Entity Tax Identification Number	99-0360497
Entity Address, Address Line One	9920 Pacific Heights Blvd
Entity Address, Address Line Two	Suite 150
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	350-4364
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Interim

Condensed Consolidated Interim Balance Sheet - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Current assets
Cash and cash equivalents	$ 6,351	$ 1,535
Prepaid expenses, taxes and other receivables	208	660
Clinical trial deposit	196	1,075
Total current assets	6,755	3,270
Property and equipment, net	691	709
Total assets	7,446	3,979
Current liabilities
Accounts payable and accrued liabilities	1,243	2,784
Total current liabilities	1,341	3,082
Milestone payment liability	183	166
Total liabilities	1,524	3,248
Stockholders' equity
Common stock Authorized 75,000 shares at March 31, 2024 (June 30, 2023 - 75,000), $0.001 par value Issued and outstanding 55,305 issued at March 31, 2024 (June 30, 2023 - 1,692)	55	2
Additional paid-in capital	153,144	141,438
Accumulated deficit	(157,550)	(151,375)
Accumulated other comprehensive income	21	21
Total stockholders' equity	5,922	731
Total liabilities and stockholders' equity	7,446	3,979
Related Party
Current liabilities
Related party payables	98	298
Preferred Stock Series A
Stockholders' equity
Preferred stock	279	279
Preferred Stock Series C
Stockholders' equity
Preferred stock	$ 9,973	$ 10,366

Condensed Consolidated Interi_2

Condensed Consolidated Interim Balance Sheet (Parenthetical) - $ / shares	Mar. 31, 2024	Jun. 30, 2023
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares issued	55,305,000	1,692,000
Preferred Stock Series A
Preferred Stock, shares issued	279,000	279,000
Preferred stock, shares outstanding	279,000	279,000
Series C Preferred Stock
Preferred Stock, shares issued	14,000	14,000
Preferred stock, shares outstanding	14,000	14,000

Condensed Consolidated Interi_3

Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Expenses
Research and development	$ 592	$ 2,005	$ 2,562	$ 7,235
General and administrative	1,493	1,297	3,504	4,212
Operating expenses	(2,085)	(3,302)	(6,066)	(11,447)
Other income (loss)
Foreign exchange	0	(1)	(8)	10
Interest, net	74	39	78	123
Other income (loss)	74	38	70	133
Net loss for the period	(2,011)	(3,264)	(5,996)	(11,314)
Computation of basic loss per share
Net loss	(2,011)	(3,264)	(5,996)	(11,314)
Series A Preferred cash dividend	(2)	(2)	(6)	(6)
Net loss for the period attributable to common stockholders	$ (2,013)	$ (3,266)	$ (6,175)	$ (11,682)
Basic and fully diluted loss per share	$ (0.05)	$ (1.94)	$ (0.37)	$ (7.32)
Basic and fully diluted weighted average number of shares	44,562,000	1,681,000	16,772,000	1,596,000
Preferred Stock Series C
Computation of basic loss per share
Preferred stock dividend			$ (173)	$ (362)

Condensed Consolidated Interi_4

Condensed Consolidated Interim Statements of Stockholders' Equity (Deficiency) (Unaudited) - USD ($) $ in Thousands	Total	Equity Line [Member]	ATM Facility [Member]	Common stock	Common stock Equity Line [Member]	Common stock ATM Facility [Member]	Additional paid-in capital	Additional paid-in capital Equity Line [Member]	Additional paid-in capital ATM Facility [Member]	Accumulated other comprehensive income	Preferred stock	Accumulated deficit
Beginning Balance at Jun. 30, 2022	$ 11,795			$ 1			$ 135,575			$ 21	$ 12,554	$ (136,356)
Beginning Balance, shares at Jun. 30, 2022				1,311,000
Issuance of shares - net of issue costs	1,903			$ 1			1,902
Issuance of shares - net of issue costs, shares				262,000
Stock option expense	518						518
Series A Preferred cash dividend	(2)											(2)
Series C Preferred stock dividend				$ 0			362					(362)
Series C Preferred stock dividend, shares				43,000
Loss for the period	(4,596)											(4,596)
Ending Balance at Sep. 30, 2022	9,618			$ 2			138,357			21	12,554	(141,316)
Ending Balance, shares at Sep. 30, 2022				1,616,000
Beginning Balance at Jun. 30, 2022	11,795			$ 1			135,575			21	12,554	(136,356)
Beginning Balance, shares at Jun. 30, 2022				1,311,000
Loss for the period	(11,314)
Ending Balance at Mar. 31, 2023	3,786			$ 2			141,156			21	10,645	(148,038)
Ending Balance, shares at Mar. 31, 2023				1,692,000
Beginning Balance at Sep. 30, 2022	9,618			$ 2			138,357			21	12,554	(141,316)
Beginning Balance, shares at Sep. 30, 2022				1,616,000
Conversion of Series C Preferred stock to common stock							1,778				(1,778)
Conversion of Series C preferred stock to common stock, shares				42,000
Additional shares issued on reverse stock split, shares				15,000
Stock option expense	436						436
Series A Preferred cash dividend	(2)											(2)
Loss for the period	(3,454)											(3,454)
Ending Balance at Dec. 31, 2022	6,598			$ 2			140,571			21	10,776	(144,772)
Ending Balance, shares at Dec. 31, 2022				1,673,000
Conversion of Series C Preferred stock to common stock							131				(131)
Conversion of Series C preferred stock to common stock, shares				3,000
Issuance of shares for services	110						110
Issuance of shares for services, shares				16
Stock option expense	290						290
Restricted stock unit expense	54						54
Series A Preferred cash dividend	(2)											(2)
Loss for the period	(3,264)											(3,264)
Ending Balance at Mar. 31, 2023	3,786			$ 2			141,156			21	10,645	(148,038)
Ending Balance, shares at Mar. 31, 2023				1,692,000
Beginning Balance at Jun. 30, 2023	731			$ 2			141,438			21	10,645	(151,375)
Beginning Balance, shares at Jun. 30, 2023				1,692,000
Issuance of shares on vesting of restricted stock units, shares				4,000
Conversion of Series C Preferred stock to common stock							37				(37)
Conversion of Series C preferred stock to common stock, shares				1,000
Stock option expense	160						160
Restricted stock unit expense	47						47
Series A Preferred cash dividend	(2)											(2)
Series C Preferred stock dividend							173					(173)
Series C Preferred stock dividend, shares				49,000
Loss for the period	(2,962)											(2,962)
Ending Balance at Sep. 30, 2023	(2,026)			$ 2			141,855			21	10,608	(154,512)
Ending Balance, shares at Sep. 30, 2023				1,746,000
Beginning Balance at Jun. 30, 2023	731			$ 2			141,438			21	10,645	(151,375)
Beginning Balance, shares at Jun. 30, 2023				1,692,000
Loss for the period	(5,996)
Ending Balance at Mar. 31, 2024	5,922			$ 55			153,144			21	10,252	(157,550)
Ending Balance, shares at Mar. 31, 2024				55,305,000
Beginning Balance at Sep. 30, 2023	(2,026)			$ 2			141,855			21	10,608	(154,512)
Beginning Balance, shares at Sep. 30, 2023				1,746,000
Issuance of shares		$ 105	$ 2,579			$ 8		$ 105	$ 2,571
Issuance of shares, shares					400,000	8,013,000
Conversion of Series C Preferred stock to common stock							356				(356)
Conversion of Series C preferred stock to common stock, shares				8,000
Stock option expense	165						165
Restricted stock unit expense	38						38
Series A Preferred cash dividend	(2)											(2)
Loss for the period	(1,023)											(1,023)
Ending Balance at Dec. 31, 2023	(164)			$ 10			145,090			21	10,252	(155,537)
Ending Balance, shares at Dec. 31, 2023				10,167,000
Issuance of shares			$ 7,892			$ 45			$ 7,847
Issuance of shares, shares						45,138,000
Stock option expense	156						156
Restricted stock unit expense	51						51
Series A Preferred cash dividend	(2)											(2)
Loss for the period	(2,011)											(2,011)
Ending Balance at Mar. 31, 2024	$ 5,922			$ 55			$ 153,144			$ 21	$ 10,252	$ (157,550)
Ending Balance, shares at Mar. 31, 2024				55,305,000

Condensed Consolidated Interi_5

Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities
Loss for the period	$ (5,996)	$ (11,314)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization of clinical trial deposit		2,150
Depreciation of property and equipment	38	45
Change in fair value of milestone liability	17	1
Stock option expense	481	1,244
Restricted stock unit expense	136	164
Changes in operating assets and liabilities
Prepaid expenses, taxes and other receivables	452	210
Clinical trial deposit	879	(1,700)
Accounts payable and accrued liabilities	(1,541)	(616)
Related party payables	(200)	(541)
Net cash used in operating activities	(5,734)	(10,357)
Cash flows from investing activities
Purchase of equipment	(20)	(232)
Net cash used in investing activities	(20)	(232)
Cash flows from financing activities
Series A Preferred cash dividend	(6)	(6)
Net cash provided by financing activities	10,570	1,854
Decrease in cash and cash equivalents	4,816	(8,735)
Cash and cash equivalents – beginning of period	1,535	11,780
Cash and cash equivalents – end of period	6,351	3,045
Equity Line [Member]
Cash flows from financing activities
Net proceeds from the issuance of shares	105	$ 1,860
ATM Facility [Member]
Cash flows from financing activities
Net proceeds from the issuance of shares	$ 10,471

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (2,011)	$ (3,264)	$ (5,996)	$ (11,314)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Nature of operations, corporate

Nature of operations, corporate history, and going concern and management plans	9 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of operations, corporate history, and going concern and management plans	1 Nature of operations, corporate history, and going concern and management plans Nature of operations Kintara Therapeutics, Inc. (the “Company”) is a clinical-stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. The Company is developing one late-stage therapeutic - REM-001 for cutaneous metastatic breast cancer (“CMBC”). In order to accelerate the Company’s development timelines, it leverages existing preclinical and clinical data from a wide range of sources. The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its current and future product candidates. Corporate history The Company is a Nevada corporation formed on June 24, 2009, under the name Berry Only, Inc. On January 25, 2013, the Company entered into and closed an exchange agreement (the “Exchange Agreement”), with Del Mar Pharmaceuticals (BC) Ltd. (“Del Mar (BC)”), 0959454 B.C. Ltd. (“Callco”), and 0959456 B.C. Ltd. (“Exchangeco”) and the security holders of Del Mar (BC). Upon completion of the Exchange Agreement, Del Mar (BC) became a wholly-owned subsidiary of the Company (the “Reverse Acquisition”). On August 19, 2020, the Company completed its merger with Adgero Biopharmaceuticals Holdings, Inc., a Delaware corporation (“Adgero”) in which Adgero continued its existence under Delaware law and became a direct, wholly-owned subsidiary of the Company. Following the completion of the merger, the Company changed its name from DelMar Pharmaceuticals, Inc. to Kintara Therapeutics, Inc. and began trading on The Nasdaq Capital Market LLC (“Nasdaq”) under the symbol “KTRA”. Kintara Therapeutics, Inc. is the parent company of Del Mar (BC), a British Columbia, Canada corporation and Adgero which are clinical-stage companies with a focus on the development of drugs for the treatment of cancer. The Company is also the parent company to Callco and Exchangeco which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition. In connection with the Adgero merger, the Company also became the parent company of Adgero Biopharmaceuticals, Inc. (“Adgero Bio”), formerly a wholly-owned subsidiary of Adgero. References to the Company refer to the Company and its wholly-owned subsidiaries. Going concern and management plans These condensed consolidated interim financial statements have been prepared on a going concern basis which assumes that the Company will continue its operations for the foreseeable future and contemplates the realization of assets and the settlement of liabilities in the normal course of business. For the nine months ended March 31, 2024, the Company reported a loss of $ 5,996 and a negative cash flow from operations of $ 5,734 . The Company had an accumulated deficit of $ 157,550 and had cash and cash equivalents of $ 6,351 as of March 31, 2024. The Company is in the clinical stage and has not generated any revenues to date. The Company does not have the prospect of achieving revenues until such time that its product candidate is commercialized, or partnered, which may not ever occur. On August 2, 2 022, the Company entered into a stock purchase agreement under which the Company has issued 662 shares of common stock for $ 2,008 in net proceeds as of March 31, 2024. In ad dition, on June 28, 2023, the Company announced that it had been awarded approximately $ 2,000 in grant funding to be received over a two-year period for its REM-001 project. During the nine months ended March 31, 2024, the Company issued an additional 53,151 shares of common stock for net proceeds of $ 10,471 from its at-the-market ( “ATM”) facility, and announced that it is suspending the development of VAL-083. Even with the proceeds from the grant funding, the stock purchase financing, and the ATM sales, the Company will require additional funding to maintain its clinical trials, research and development projects, and for general operations. These circumstances indicate substantial doubt exists about the Company’s ability to continue as a going concern within one year from the date of filing of these condensed consolidated interim financial statements. On April 2, 2024, the Company entered into a merger agreement with TuHURA Biosciences, Inc. (Note 10). Consequently, management is pursuing various financing alternatives to fund the Company’s operations so it can continue as a going concern. Management plans to continue to pursue opportunities to secure the necessary financing through the issue of new equity, including debt, entering into strategic partnership arrangements, and/or pursuing additional strategic transactions in the event the Company does not receive stockholder approval for the proposed merger transaction or the merger is not otherwise consummated. However, the Company’s ability to raise additional capital could be affected by various risks and uncertainties including, but not limited to, global unrest. The Company may not be able to raise sufficient additional capital and may need to tailor its drug candidate development programs based on the amount of funding the Company is able to raise in the future. Nevertheless, there is no assurance that these initiatives will be successful. These condensed consolidated interim financial statements do not give effect to any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
Significant Accounting Policies	Mar. 31, 2024
Accounting Policies [Abstract]
Significant accounting policies	2 Significant accounting policies Reverse stock split On November 10, 2022, the Company filed a Certificate of Change to the Company’s Articles of Incorporation, as amended, in order to effectuate a 1: 50 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock as well as its authorized shares of common stock. As a result of the Reverse Stock Split, every 50 shares of issued and outstanding common stock were converted into one share of common stock with a proportionate reduction in the Company's authorized shares of common stock. Any fractional shares of common stock resulting from the Reverse Stock Split were rounded up to the nearest whole post-Reverse Stock Split share. The Reverse Stock Split did not change the par value of the Company's common stock. All outstanding securities entitling their holders to acquire shares of common stock were adjusted as a result of the Reverse Stock Split. All common share and per share data are retrospectively restated to give effect to the Reverse Stock Split for all periods presented herein. Basis of presentation The condensed consolidated interim financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and are presented in United States dollars. The functional currency of the Company and each of its subsidiaries is the United States dollar. The accompanying condensed consolidated interim financial statements include the accounts of the Company and its wholly-owned subsidiaries, Adgero, Adgero Bio, Del Mar (BC), Callco, and Exchangeco. All intercompany balances and transactions have been eliminated in consolidation. The principal accounting policies applied in the preparation of these condensed consolidated interim financial statements are set out below and have been consistently applied to all periods presented. Unaudited interim financial data The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated interim financial statements should be read in conjunction with the June 30, 2023, audited consolidated financial statements of the Company included in the Company’s Form 10-K filed with the SEC on September 18, 2023. In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for a fair presentation. The results for nine months ended March 31, 2024, are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2024, or for any other future annual or interim period. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the valuation of equity instruments issued for services, milestone payment liability, and clinical trial accruals. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these condensed consolidated interim financial statements. Loss per share Income or loss per share is calculated based on the weighted average number of common shares outstanding. For the nine-month periods ended March 31, 2024, and 2023, diluted loss per share does not differ from basic loss per share since the effect of the Company’s warrants, stock options, restricted stock units, and convertible preferred shares is anti-dilutive. As of March 31, 2024, potential common shares of 693 (2023 – 713 ) related to outstanding common share warrants, 42 (2023 – 42 ) related to outstanding Series C preferred stock warrants, 222 (2023 – 198 ) related to stock options, 66 (2023 - 18 ) related to restricted stock units, and 235 (2023 – 245 ) relating to outstanding Series C convertible preferred shares were excluded from the calculation of net loss per common share. Government assistance Government grants, including grants from similar bodies, are recognized when there is reasonable assurance that the Company has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received. Grants that compensate the Company for expenses incurred are recognized in income or loss in reduction thereof in the same period in which the expenses are recognized. The Company uses a net presentation basis whereby the grant offsets the research and development expenses as it is being recovered under the grant program. Recently issued accounting standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s condensed consolidated interim financial statements.

Clinical Trial Deposit

Clinical Trial Deposit	9 Months Ended
Clinical Trial Deposit	Mar. 31, 2024
Other Liabilities [Abstract]
Clinical Trial Deposit	3 Clinical trial deposit In October 2020, the Company announced that it had entered into a final agreement with a contract research organization (“CRO”) for the management of the Company’s registrational study of VAL-083 for glioblastoma. Under the agreement, the Company supplied the drug for the study and the CRO managed all operational aspects of the study including site activation and patient enrollment. The Company was required to make certain payments under the agreement related to patient enrollment milestones. For the three and nine months ended March 31, 2024, the Company has recognized a recovery of $ 512 (2023 - $ 1,075 expense) and an expense of $ 563 (2023 - $ 3,990 ), respectively, for this study in relation to clinical site initiation and patient enrollment. On October 31, 2023, the Company announced that preliminary topline results from this registrational study for VAL-083 did not perform better than the current standards of care in glioblastoma. As a result, the Company announced that it has terminated the development of VAL-083. In the nine months ended March 31, 2024, the remaining deposit of $ 1,075 was offset against amounts owing to the CRO and the agreement with the CRO was terminated with an additional final cost of $ 1,000 , which was paid in the nine months ended March 31, 2024. In the nine months ended March 31, 2024, the Company recorded $ 196 as a deposit with a CRO for the management of the Company’s 15-patient study of REM-001 for cutaneous metastatic breast cancer (“CMBC”).

Clinical Trials Grant

Clinical Trials Grant	9 Months Ended
Clinical Trials Grant	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Clinical Trials Grant	4 Clinical trials grant Effective July 1, 2023, the Company was awarded a $ 2,000 Small Business Innovation Research grant from the National Institutes of Health ("NIH") to support the clinical development of REM-001 for the treatment of cutaneous metastatic breast cancer. The grant will be received in two tranches: approximately $ 1,250 for the period July 1, 2023, to June 30, 2024, and approximately $ 750 for the period July 1, 2024, to June 30, 2025. As a result of receiving the grant, the REM-001, 15-patient clinical trial will be re-started. The grant is expended to the Company as a reimbursement of expenditures incurred. During the three and nine months ended March 31, 2024, the Company received $ 194 (2023 - nil ) and $ 404 (2023 - nil ), respectively, for grants received against research and development expenditures in the period. The grant is subject to various performance conditions and funding risk where the financial conditions of the NIH may change from time to time. The Company recognizes the grant only to the extent there is reasonable assurance the grant will be funded to the Company.

Property and Equipment, Net

Property and Equipment, Net	9 Months Ended
Property and Equipment, Net	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	5 Property and equipment, net $ Balance, June 30, 2023 709 Additions 20 Depreciation ( 38 ) Balance, March 31, 2024 691 At March 31, 2024, the total capitalized cost of property and equipment was $ 879 (June 30, 2023 - $ 859 ), of which $ 599 is not in use. The Company has recognized $ 38 (2023 - $ 45 ) in depreciat ion expense in the nine months ended March 31, 2024, on equipment in use.

Related Party Transactions

Related Party Transactions	9 Months Ended
Related Party Transactions	Mar. 31, 2024
Related Party Transactions [Abstract]
Related party transactions	6 Related party transactions Valent Technologies, LLC Agreements On November 20, 2023, Dr. Brown was terminated from his position as the Company’s Chief Scientific Officer as a result of cost-cutting measures adopted by the Company; he remains a consultant to the Company. Dr. Brown is a principal of Valent Technologies, LLC (“Valent”) and as a result Valent is a related party to the Company. On September 12, 2010, the Company entered into a Patent Assignment Agreement (the “Valent Assignment Agreement”) with Valent pursuant to which Valent transferred to the Company all its right, title and interest in, and to, the patents for VAL-083 owned by Valent. The Company now owns all rights and title to VAL-083 and is responsible for further development and commercialization. In accordance with the terms of the Valent Assignment Agreement, Valent is entitled to receive a future royalty on all revenues derived from the development and commercialization of VAL-083. In the event that the Company terminates the agreement, the Company may be entitled to receive royalties from Valent’s subsequent development of VAL-083 depending on the development milestones the Company has achieved prior to the termination of the Valent Assignment Agreement. On September 30, 2014, the Company entered into an exchange agreement (the “Valent Exchange Agreement”) with Valent and Del Mar (BC). Pursuant to the Valent Exchange Agreement, Valent exchanged its loan payable in the outstanding amount of $ 279 (including aggregate accrued interest to September 30, 2014, of $ 29 ), issued to Valent by Del Mar (BC), for 279 shares of the Company’s Series A Preferred Stock. The Series A Preferred Stock has a stated value of $ 1.00 per share (the “Series A Stated Value”) and is not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3 % of the Series A Stated Value per year, payable quarterly in arrears. For the three and nine months ended March 31, 2024, the Company recorded $ 2 (2023 - $ 2 ) and $ 6 (2023 - $ 6 ), respectively, re lated to the dividends paid to Valent. The dividends have been recorded as a direct increase in accumulated deficit. On February 13, 2024, the Company sent an Opt-Out Notice to Valent under the Valent Assignment Agreement whereby the Company assigned all rights, title and interest in and to the patents for VAL-083 to Valent. As a result, the Company granted Valent a non-exclusive, fully-paid, royalty-free, perpetual, worldwide and non-transferable license, subject to limited exceptions. The Company is entitled to receive royalties from Valent’s subsequent commercialization of VAL-083 equal to 5 % of Valent Net Sales (as defined in the Valent Assignment Agreement).

Stockholders' Equity

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Mar. 31, 2024
Equity [Abstract]
Stockholders' Equity	7 Stockholders’ equity Preferred stock Series C Preferred Stock Series C Preferred Stock Number $ Balance – June 30, 2023 14,208 10,366 Conversion of Series C Preferred stock to common stock ( 540 ) ( 393 ) Balance – March 31, 2024 13,668 9,973 In August 2020, the Company issued 25,028 shares of Series C Convertible Preferred Stock (the “Series C Preferred Stock”) in three separate closings of a private placement (Series C-1, C-2, and C-3). Each share of Series C Preferred Stock was issued at a purchase price of $ 1,000 per share and is convertible into shares of common stock based on the respective conversion prices which were determined at the closing of each round of the private placement. The conversion prices for the Series C-1 Preferred Stock, Series C-2 Preferred Stock, and the Series C-3 Preferred Stock are $ 58.00 , $ 60.70 , and $ 57.50 , respectively. Subject to ownership limitations, the owners of the Series C-1 Preferred Stock, the Series C-2 Preferred Stock, and the Series C-3 Preferred Stock are entitled to receive dividends, payable in shares of common stock at a rate of 10 %, 15 %, 20 % and 25 %, respectively, of the number of shares of common stock issuable upon conversion of the Series C Preferred Stock, on the 12th, 24th, 36th and 48th month, anniversary of the initial closing of the private placement. The Company paid the 12th, 24th, and 36th month anniversary dividends of 10 %, 15 %, and 20 % common stock dividends on August 19, 2021, 2022, and 2023, respectively. The Series C Preferred Stock dividends do not require declaration by the board of directors and are accrued annually as of the date the dividend is earned in an amount equal to the fair value of the Company’s common stock on the dates the respective dividends are paid. The fair value of the Series C Preferred Stock dividend paid on August 19, 2023, was determined by multiplying the dividends paid of 49 shares of common stock by the Company’s closing share price on August 18, 2023, of $ 3.53 per share for a total fair value of $ 173 . Any outstanding shares of Series C Preferred Stock will automatically convert to shares of common stock on August 19, 2024. In addition, as part of the Series C Preferred financing, the Company issued warrants to the placement agent (“Series C Agent Warrants”). The Series C Preferred Stock shall with respect to distributions of assets and rights upon the occurrence of a liquidation, rank (i) senior to the Company’s common stock and (ii) senior to any other class or series of capital stock of the Company hereafter created which does not e xpressly rank pari passu with, or senior to, the Series C Preferred Stock. The Series C Preferred Stock is pari passu in liquidation to the Company’s Series A Preferred Stock. The liquidation value of the Series C Preferred Stock at March 31, 2024, is the stated value of $ 9,973 (J une 30, 2023 - $ 10,366 ). The Company’s Series C Preferred Stock outstanding, conversion shares, and aggregate dividends as of March 31, 2024, are as follows: Series Number Conversion Number of Dividend Shares (in thousands) Series 1 10,925 58.00 188 151 Series 2 898 60.70 15 10 Series 3 1,845 57.50 32 24 13,668 235 185 Series C Dividends Dividend Shares 10% - August 19, 2021 (actual) 34 15% - August 19, 2022 (actual) 43 20% - August 19, 2023 (actual) 49 25% - August 19, 2024 (estimated) 59 185 Series A Preferred Stock Effective September 30, 2014, the Company filed a Certificate of Designation of Series A Preferred Stock (the “Series A Certificate of Designation”) with the Secretary of State of Nevada. Pursuant to the Series A Certificate of Designation, the Company designated 279 shares of preferred stock as Series A Preferred Stock. The shares of Series A Preferred Stock have a stated value of $ 1.00 per share (the “Series A Stated Value”) and are not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3 % of the Series A Stated Value per year, payable quarterly in arrears. Upon any liquidation of the Company, the holder of the Series A Preferred Stock will be entitled to be paid, out of any assets of the Company available for distribution to stockholders, the Series A Stated Value of the shares of Series A Preferred Stock held by such holder, plus any accrued but unpaid dividends thereon, prior to any payments being made with respect to the common stock. The Series A Preferred Stock is held by Valent (note 6). The Series A Preferred Stock shall with respect to distributions of assets and rights upon the occurrence of a liquidation, rank (i) senior to the Company’s common stock, and (ii) senior to any other class or series of capital stock of the Company hereafter created which does not expressly rank pari passu with, or senior to, the Series A Preferred Stock. The Series A Preferred Stock is pari passu in liquidation to the Company’s Series C Preferred Stock. The liquidation value of the Series A Preferred stock at March 31, 2024, is its stated value of $ 279 (Jun e 30, 2023 - $ 279 ). There was no change to the Series A Preferred stock for the nine months ended March 31, 2024, or 2023. Common stock Common stock issuances during the nine months ended March 31, 2024 On September 19, 2023, the Company entered into a Sales Agreement, (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “Agent”) pursuant to which the Company may offer and sell, from time to time, through the Agent, as sales agent and/or principal, shares of common stock having an aggregate offering price of up to $ 2,850 (the “ATM Facility”), subsequently increased to $ 10,900 on December 18, 2023. From October 31, 2023, until March 31, 2024, the Company raised $ 10,471 in net proceeds, after deducting share issuance costs of $ 435 , from the sale of 53,151 shares of its common stock at a weighted average price of $ 0.21 per share under the ATM Facility. On February 22, 2024, the Company determined that it had concluded utilization of the ATM Facility. Sales of the shares of common stock made under the ATM Facility may be made in negotiated transactions, or by any method permitted by law that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on The Nasdaq Capital Market or sales made to or through a market maker other than on an exchange. Pursuant to the Sales Agreement, the Company has the right, in its sole discretion, to present the Agent with a placement notice directing the Agent to purchase a number of shares of common stock under the ATM Facility, subject to the terms and conditions of the Sales Agreement. The purchase price per share under the ATM Facility will be based on market prices of the common stock on the applicable purchase date for such purchases. The Agent is entitled to a commission rate of 3.0 % of the gross sales price per share sold under the Sales Agreement. During the nine months ended March 31, 2024, the Company sold 400 shares of common stock at a weighted average price of $ 0.23 per share for total net proceeds of approximately $ 105 under the Purchase Agreemen t with Lincoln Park (as defined below). During the nine months ended March 31, 2024, the Company issued 4 shares of common stock on vesting of restricted stock units during the period. On February 22, 2024, the Company determined that it had concluded utilization of the equity facility pursuant to the terms of the Purchase Agreement with Lincoln Park. Common stock issuances during the nine months ended March 31, 2023 On August 2, 2022, the Company entered into a stock purchase agreement, dated as of August 2, 2022, (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park committed to purchase up to a maximum of $ 20,000 of shares of the Company’s common stock (the “Purchase Shares”). Concurrently with entering into the Purchase Agreement, the Company also entered into a registration rights agreement with Lincoln Park, pursuant to which it agreed to take certain actions relating to the registration of the offer and sale of the Purchase Shares available for issuance under the Purchase Agreement. Upon execution of the Purchase Agreement, the Company issued 33 shares of common stock to Lincoln Park as a commitment fee in connection with entering into the Purchase Agreement. Pursuant to the Purchase Agreement, the Company has the right, in its sole discretion, to present Lincoln Park with a purchase notice directing Lincoln Park to purchase up to 10 Purchase Shares provided that the closing sale price of the common stock on the purchase date is not below a threshold price set forth in the Purchase Agreement (a “Regular Purchase”). The Company and Lincoln Park may mutually agree to increase the Regular Purchase amount with respect to any Regular Purchase under the Purchase Agreement, provided that Lincoln Park’s maximum committed purchase obligation under any single Regular Purchase shall not exceed $ 2,000 . The purchase price per share for each Regular Purchase is based on prevailing market prices of the common stock immediately preceding the time of sale as computed in accordance with the terms set forth in the Purchase Agreement. There are no upper limits on the price per share that Lincoln Park must pay for the Purchase Shares under the Purchase Agreement. If the Company directs Lincoln Park to purchase the maximum number of shares of common stock that the Company may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the Purchase Agreement, the Company may direct Lincoln Park to purchase additional shares of common stock in an “accelerated purchase” (each, an “Accelerated Purchase”) and an “additional accelerated purchase” (each, an “Additional Accelerated Purchase”) (including multiple Additional Accelerated Purchases on the same trading day) as provided in the Purchase Agreement. The purchase price per share for each Accelerated Purchase and Additional Accelerated Purchase will be based on market prices of the common stock on the applicable purchase date for such Accelerated Purchases and such Additional Accelerated Purchases. During the nine months ended March 31, 2024, the Company received stockholder approval to issue 20 % or more of its outstanding shares as of the date the Company entered into the Purchase Agreement with Lincoln Park. The Purchase Agreement may be terminated by the Company at any time, at its sole discretion, without any cost or penalty, by giving one business day notice to Lincoln Park to terminate the Purchase Agreement. During the nine months ended March 31, 2023, the Company sold 229 shares of common stock for total net proceeds of approximately $ 1,860 under this Purchase Agreemen t. 2017 Omnibus Incentive Plan As subsequently approved by the Company’s stockholders at an annual meeting of stockholders, on April 11, 2018, the Company’s board of directors approved the adoption of the Company’s 2017 Omnibus Equity Incentive Plan (the “2017 Plan”), as amended. The board of directors also approved a form of Performance Stock Unit Award Agreement to be used in connection with grants of performance stock units (“PSUs”) as well as a Restricted Stock Unit ("RSU") award under the 2017 Plan. As approved by the Company’s stockholders on June 21, 2022, the number of common shares available under the 2017 Plan as of March 31, 2024, is 440 shares, less the numbe r of shares of common stock issued under the Del Mar (BC) 2013 Amended and Restated Stock Option Plan (the “Legacy Plan”), or that are subject to grants of stock options made, or that may be made, under the Legacy Plan, or that have been previously exercised. The following table sets forth the aggregate information on all equity compensation plans as of March 31, 2024: Plan (in thousands, except per share amounts) Number of shares of common stock to be issued upon exercise of outstanding stock options and rights Weighted-average exercise price of stock options and rights Number of shares of common stock remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (2) Equity compensation plans approved by security holders - 2017 Plan (1) 222 21.40 144 Equity compensation plans not approved by security holders - Del Mar (BC) 2013 Amended and Restated Stock Option Plan — 2,060.08 — Totals 222 32.92 144 (1) The Del Mar (BC) 2013 Amended and Restated Stock Option Plan refers to the Company’s previous equity compensation plan. (2) The balance of 144 shares of common stock available for issuance under the 2017 Plan as of March 31, 2024, is net of stock options previously exercised. The maximum number of shares of Company common stock with respect to which any one participant may be granted awards during any calendar year is 8 % of the Company’s fully diluted shares of common stock on the date of grant (excluding the number of shares of common stock issued under the 2017 Plan and/or the Legacy Plan or subject to outstanding awards granted under the 2017 Plan and/or the Legacy Plan). No award will be granted under the 2017 Plan on, or after, July 7, 2027. Stock options During the nine months ended March 31, 2024, a total of 89 stock options to purchase shares of common stock at an exercise price of $ 4.655 per share were granted to directors and officers of the Company. The 26 options granted to non-employee directors vest pro rata monthly over 12 months commencing on March 31, 2024. The remaining 63 options granted to executive officers, employees and consultants vest as to 25 % on the first anniversary of grant with the remaining portion vesting pro rata monthly thereafter over 36 months. All of the options to purchase shares of common stock granted have a 10 -year term and are subject to cancellation upon the grantees’ termination of service for the Company, with certain exceptions. The following table sets forth changes in stock options outstanding under all plans: Number of Weighted Balance – June 30, 2023 198 51.71 Granted 89 4.66 Expired ( 34 ) 107.69 Forfeited ( 31 ) 8.26 Balance – March 31, 2024 222 30.70 The following table summarizes stock options outstanding and exercisable under all plans at March 31, 2024: Exercise price Number Weighted Number 4.66 79 9.42 15 6.04 9 8.89 2 8.79 34 8.34 14 12.75 to 16.25 6 8.53 6 30.50 to 48.00 73 7.56 44 62.00 to 68.50 13 7.06 13 85.00 7 6.46 7 304.95 to 2,660.00 1 2.11 1 222 102 Stock options granted during the nine months ended March 31, 2024, have been valued using a Black-Scholes pricing model with the following assumptions: March 31, 2024 Dividend rate — % Estimated volatility 91.40 % Risk-free interest rate 4.24 % Expected term – years 6.08 The estimated volatility of the Company’s common stock at the date of issuance of the stock options is based on the historical volatility of the Company. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining term of the stock options at the valuation date. The expected term of the stock options has been estimated using the plain vanilla method. The Company has recognized the following amounts as stock option expense for the periods noted (in thousands): Three months ended Nine months ended 2024 2023 2024 2023 Research and development 50 94 143 368 General and administrative 106 196 338 876 156 290 481 1,244 All of the stock option expense for the periods ended March 31, 2024, and 2023, has been recognized as additional paid in capital. The aggregate intrinsic value of stock options outstanding as well as stock options exercisable was nil as of March 31, 2024, and 2023, respectively. As of March 31, 2024, there was $ 447 in unrecognized compensation expense that will be recognized over the next 2.2 years. The following table sets forth changes in unvested stock options under all plans: Number of Weighted Unvested at June 30, 2023 118 24.12 Granted 89 4.66 Vested ( 56 ) 19.31 Forfeited ( 31 ) 8.26 Unvested at March 31, 2024 120 16.07 The aggregate intrinsic value of unvested stock options at March 31, 2024, was nil (2023 - nil ). The unvested stock options have a remaining weighted average contractual term of 8.76 years (2023 – 9.03 ). Restricted stock units During the nine months ended March 31, 2024, the Company recognized a total of $ 136 (2023 - 54 ) in compensation expense related to RSUs. Number of Balance – June 30, 2023 78 Issuance of restricted stock units — Vesting of restricted stock units ( 4 ) Forfeiture of restricted stock units ( 8 ) Balance – March 31, 2024 66 Common stock warrants The following table sets forth changes in outstanding common stock warrants: Number of Weighted Balance – June 30, 2023 713 43.55 Expiry of warrants issued for services ( 20 ) 57.14 Balance – March 31, 2024 693 43.12 The following table summarizes the Company’s outstanding common stock warrants as of March 31, 2024: Description of warrants Number Exercise Expiry date 2022 April Investor warrants 325 20.50 April 14, 2027 2022 Investor warrants 240 62.50 March 28, 2025 2020 Investor warrants 65 50.00 August 16, 2024 2019 Investor warrants 15 155.00 June 5, 2024 NBTS Warrants 3 54.50 June 19, 2025 2022 April Agent warrants 32 33.12 October 14, 2026 2022 Agent warrants 12 78.12 March 28, 2025 2019 Agent warrants 1 193.75 June 3, 2024 693 Series C Preferred Stock warrants In connection with the Series C Preferred Stock private placement, the Company issued 2,504 Series C Agent Warrants. The Series C Agent Warrants have an exercise price of $ 1,000 per share, provide for a cashless exercise feature, and are exercisable for a period of four years from August 19, 2020. The Series C Preferred Stock issuable upon exercise of the Series C Agent Warrants is convertible into shares of common stock in the same manner as each respective underlying series of outstanding Series C Preferred Stock and will be entitled to the same dividend rights as each respective series. The following table sets forth changes in outstanding Series C Agent Warrants: Balance Number of Number of Balance, Conversion Preferred Series C-1 Agent Warrants 1,929 — — 1,929 58.00 Preferred Series C-2 Agent Warrants 219 — — 219 60.70 Preferred Series C-3 Agent Warrants 296 — — 296 57.50 2,444 — — 2,444 The following table summarizes the Company’s outstanding Series C Agent Warrants as of March 31, 2024: Series C Agent Warrants Number Conversion Number of Cumulative Series 1 1,929 58.00 33 23 Series 2 219 60.70 4 3 Series 3 296 57.50 5 4 2,444 42 30

Supplementary Statement of Cash

Supplementary Statement of Cash Flows Information	9 Months Ended
Supplementary Statement of Cash Flows Information	Mar. 31, 2024
Supplemental Cash Flow Elements [Abstract]
Supplementary statement of cash flows information	8 Supplementary statement of cash flows information The Company incurred the following non-cash investing and financing transactions (in thousands): Nine months ended 2024 2023 Series C Preferred Stock common stock dividend (note 7) 173 362 Non-cash issue costs (note 7) — 289 Equipment additions reclassified from prepaid expenses — 447 Income taxes paid — — Interest paid — —

Financial instruments

Financial instruments	9 Months Ended
Financial instruments	Mar. 31, 2024
Investments, All Other Investments [Abstract]
Financial Instruments	9 Financial instruments The Company's financial instruments are measured at fair value as determined by using the fair value hierarchy for inputs that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:  Level one - inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities;  Level two - inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals; and  Level three - unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. As of March 31, 2024, the Company’s milestone payment liability was measured using level 3 inputs. The milestone payment liability relates to contingent milestone payments for the REM-001 program that was acquired in the Adgero merger (note 1). March 31, 2024 Liability Level 1 Level 2 Level 3 Milestone payment liability — — 183 $ Balance – June 30, 2023 166 Change in fair value estimate 17 Balance – March 31, 2024 183 The Company’s financial instruments consist of cash and cash equivalents, other receivables, accounts payable, and related party payables. The carrying values of cash and cash equivalents, other receivables, accounts payable and related party payables approximate their fair values due to the immediate or short-term maturity of these financial instruments.

Subsequent Events

Subsequent Events	9 Months Ended
Subsequent Events	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent events	10 Subsequent events The Company has evaluated its subsequent events from March 31, 2024, through the date these condensed consolidated interim financial statements were issued and has determined that there are no subsequent events requiring disclosure in these condensed consolidated interim financial statements other than the items noted below. Merger with TuHURA Biosciences, Inc. On April 2, 2024, the Company, Kayak Mergeco, Inc., a wholly-owned subsidiary of Kintara incorporated in the State of Dela ware (“Merger Sub”), and TuHURA Biosciences, Inc., a Delaware corporation (“TuHURA”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which Merger Sub will merge with and into TuHURA, with TuHURA surviving the merger and becoming a direct, wholly-owned subsidiary of the Company (the “Merger”). Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the “Effective Time”), (i) each then-outstanding share of TuHURA common stock, par value $ 0.001 per share (the “TuHURA Common Stock”) (other than any shares held in treasury and Dissenting Shares (as defined in the Merger Agreement)) will be converted into shares of the Company’s common stock equal to the Exchange Ratio, as such term is defined in the Merger Agreement, (ii) each then-outstanding TuHURA stock option will be assumed and converted into an option to purchase shares of the Company’s common stock, subject to certain adjustments as set forth in the Merger Agreement, and (iii) each then-outstanding warrant to purchase shares of TuHURA Common Stock (the “TuHURA Warrants”) will be assumed and converted into and exchangeable for a warrant of like tenor entitling the holder to purchase shares of the Company’s common stock, subject to certain adjustments as set forth in the Merger Agreement. In addition to the foregoing, the Merger Agreement provides that, at the closing of the Merger, the corporate name of the Company will be changed to “TuHURA Biosciences, Inc.” Existing Company stockholders will receive contingent value rights (“CVR”), entitling them to receive shares of the Company's common stock upon achievement of enrollment of a minimum of 10 patients in the REM-001 clinical trial, with such patients each completing 8 weeks of follow-up on or before December 31, 2025. Under the terms of the Merger Agreement, on a pro forma basis, post-merger Company stockholders are expected to collectively own approximately 2.85 %, or approximately 5.45 % including the shares underlying the CVR, of the common stock of the post-merger combined company on a pro forma fully diluted basis. TuHURA stockholders are expected to collectively own approximately 97.15 %, or 94.55 % assuming the distribution of the CVR shares, of the common stock of the combined company on a pro forma fully diluted basis. The transaction is expected to close in the third calendar quarter of 2024 and remains subject to stockholder and regulatory approval. Termination Fees Payable by Kintara If the Merger Agreement is terminated by either Kintara or TuHURA under certain circumstances, Kintara must pay TuHURA a termination fee of $ 1,000 . If TuHURA terminates the Merger Agreement under certain circumstances, Kintara must reimburse TuHURA for expenses incurred by TuHURA in connection with the Merger Agreement and the transactions contemplated thereby, up to a maximum of $ 750 . Compensation Matters On April 2, 2024, the Board approved a one-time special bonus to Mr. Hoffman in the amount of $ 327 for his service as the Company’s Chief Executive Officer. On April 2, 2024, the Board agreed to (i) resume payment of fees earned by non-employee directors for serving on the Board and (ii) pay an aggregate of $ 93 in accrued fees to such directors.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Mar. 31, 2024
Accounting Policies [Abstract]
Reverse Stock Split	Reverse stock split On November 10, 2022, the Company filed a Certificate of Change to the Company’s Articles of Incorporation, as amended, in order to effectuate a 1: 50 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock as well as its authorized shares of common stock. As a result of the Reverse Stock Split, every 50 shares of issued and outstanding common stock were converted into one share of common stock with a proportionate reduction in the Company's authorized shares of common stock. Any fractional shares of common stock resulting from the Reverse Stock Split were rounded up to the nearest whole post-Reverse Stock Split share. The Reverse Stock Split did not change the par value of the Company's common stock. All outstanding securities entitling their holders to acquire shares of common stock were adjusted as a result of the Reverse Stock Split. All common share and per share data are retrospectively restated to give effect to the Reverse Stock Split for all periods presented herein.
Basis of Presentation	Basis of presentation The condensed consolidated interim financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and are presented in United States dollars. The functional currency of the Company and each of its subsidiaries is the United States dollar. The accompanying condensed consolidated interim financial statements include the accounts of the Company and its wholly-owned subsidiaries, Adgero, Adgero Bio, Del Mar (BC), Callco, and Exchangeco. All intercompany balances and transactions have been eliminated in consolidation. The principal accounting policies applied in the preparation of these condensed consolidated interim financial statements are set out below and have been consistently applied to all periods presented.
Unaudited Interim Financial Data	Unaudited interim financial data The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated interim financial statements should be read in conjunction with the June 30, 2023, audited consolidated financial statements of the Company included in the Company’s Form 10-K filed with the SEC on September 18, 2023. In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for a fair presentation. The results for nine months ended March 31, 2024, are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2024, or for any other future annual or interim period.
Use of Estimates	Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the valuation of equity instruments issued for services, milestone payment liability, and clinical trial accruals. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these condensed consolidated interim financial statements.
Loss Per Share	Loss per share Income or loss per share is calculated based on the weighted average number of common shares outstanding. For the nine-month periods ended March 31, 2024, and 2023, diluted loss per share does not differ from basic loss per share since the effect of the Company’s warrants, stock options, restricted stock units, and convertible preferred shares is anti-dilutive. As of March 31, 2024, potential common shares of 693 (2023 – 713 ) related to outstanding common share warrants, 42 (2023 – 42 ) related to outstanding Series C preferred stock warrants, 222 (2023 – 198 ) related to stock options, 66 (2023 - 18 ) related to restricted stock units, and 235 (2023 – 245 ) relating to outstanding Series C convertible preferred shares were excluded from the calculation of net loss per common share.
Government Assistance	Government assistance Government grants, including grants from similar bodies, are recognized when there is reasonable assurance that the Company has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received. Grants that compensate the Company for expenses incurred are recognized in income or loss in reduction thereof in the same period in which the expenses are recognized. The Company uses a net presentation basis whereby the grant offsets the research and development expenses as it is being recovered under the grant program.
Recently Issued Accounting Standards	Recently issued accounting standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s condensed consolidated interim financial statements.

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	9 Months Ended
Property and Equipment, Net (Tables)	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	$ Balance, June 30, 2023 709 Additions 20 Depreciation ( 38 ) Balance, March 31, 2024 691

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
Stockholders' Equity (Tables)	Mar. 31, 2024
Class Of Stock [Line Items]
Summary of Aggregate Information on all Equity Compensation Plans	The following table sets forth the aggregate information on all equity compensation plans as of March 31, 2024: Plan (in thousands, except per share amounts) Number of shares of common stock to be issued upon exercise of outstanding stock options and rights Weighted-average exercise price of stock options and rights Number of shares of common stock remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (2) Equity compensation plans approved by security holders - 2017 Plan (1) 222 21.40 144 Equity compensation plans not approved by security holders - Del Mar (BC) 2013 Amended and Restated Stock Option Plan — 2,060.08 — Totals 222 32.92 144 (1) The Del Mar (BC) 2013 Amended and Restated Stock Option Plan refers to the Company’s previous equity compensation plan. (2) The balance of 144 shares of common stock available for issuance under the 2017 Plan as of March 31, 2024, is net of stock options previously exercised.
Schedule of Stock Option Expense	Three months ended Nine months ended 2024 2023 2024 2023 Research and development 50 94 143 368 General and administrative 106 196 338 876 156 290 481 1,244
Schedule of Unvested Stock Options	Number of Weighted Unvested at June 30, 2023 118 24.12 Granted 89 4.66 Vested ( 56 ) 19.31 Forfeited ( 31 ) 8.26 Unvested at March 31, 2024 120 16.07
Schedule of Restricted Stock Units	Number of Balance – June 30, 2023 78 Issuance of restricted stock units — Vesting of restricted stock units ( 4 ) Forfeiture of restricted stock units ( 8 ) Balance – March 31, 2024 66
Schedule of Warrants	Number of Weighted Balance – June 30, 2023 713 43.55 Expiry of warrants issued for services ( 20 ) 57.14 Balance – March 31, 2024 693 43.12
Schedule of Changes in Outstanding Warrants	Description of warrants Number Exercise Expiry date 2022 April Investor warrants 325 20.50 April 14, 2027 2022 Investor warrants 240 62.50 March 28, 2025 2020 Investor warrants 65 50.00 August 16, 2024 2019 Investor warrants 15 155.00 June 5, 2024 NBTS Warrants 3 54.50 June 19, 2025 2022 April Agent warrants 32 33.12 October 14, 2026 2022 Agent warrants 12 78.12 March 28, 2025 2019 Agent warrants 1 193.75 June 3, 2024 693
Series C Warrants
Class Of Stock [Line Items]
Schedule of Changes in Outstanding Warrants	The following table summarizes the Company’s outstanding Series C Agent Warrants as of March 31, 2024: Series C Agent Warrants Number Conversion Number of Cumulative Series 1 1,929 58.00 33 23 Series 2 219 60.70 4 3 Series 3 296 57.50 5 4 2,444 42 30
Schedule of Conversion of Series C Preferred Stock to Series C Warrants	Balance Number of Number of Balance, Conversion Preferred Series C-1 Agent Warrants 1,929 — — 1,929 58.00 Preferred Series C-2 Agent Warrants 219 — — 219 60.70 Preferred Series C-3 Agent Warrants 296 — — 296 57.50 2,444 — — 2,444
Stock options [Member]
Class Of Stock [Line Items]
Schedule of Outstanding Under the Legacy Plan	Number of Weighted Balance – June 30, 2023 198 51.71 Granted 89 4.66 Expired ( 34 ) 107.69 Forfeited ( 31 ) 8.26 Balance – March 31, 2024 222 30.70
Summary of Stock Options Currently Outstanding and Exercisable	Exercise price Number Weighted Number 4.66 79 9.42 15 6.04 9 8.89 2 8.79 34 8.34 14 12.75 to 16.25 6 8.53 6 30.50 to 48.00 73 7.56 44 62.00 to 68.50 13 7.06 13 85.00 7 6.46 7 304.95 to 2,660.00 1 2.11 1 222 102
Schedule of Valuation Assumptions Using a Black-Scholes Pricing Model	March 31, 2024 Dividend rate — % Estimated volatility 91.40 % Risk-free interest rate 4.24 % Expected term – years 6.08
Performance stock units [Member]
Class Of Stock [Line Items]
Schedule of Issuance of Series C Preferred Stock	Series C Preferred Stock Number $ Balance – June 30, 2023 14,208 10,366 Conversion of Series C Preferred stock to common stock ( 540 ) ( 393 ) Balance – March 31, 2024 13,668 9,973
Schedule of Series C Preferred Stock Outstanding, Conversion Shares and Aggregate Dividends	The Company’s Series C Preferred Stock outstanding, conversion shares, and aggregate dividends as of March 31, 2024, are as follows: Series Number Conversion Number of Dividend Shares (in thousands) Series 1 10,925 58.00 188 151 Series 2 898 60.70 15 10 Series 3 1,845 57.50 32 24 13,668 235 185 Series C Dividends Dividend Shares 10% - August 19, 2021 (actual) 34 15% - August 19, 2022 (actual) 43 20% - August 19, 2023 (actual) 49 25% - August 19, 2024 (estimated) 59 185

Supplementary Statement of Ca_2

Supplementary Statement of Cash Flows Information (Tables)	9 Months Ended
Supplementary Statement of Cash Flows Information (Tables)	Mar. 31, 2024
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplementary Statement of Cash Flows Information	Nine months ended 2024 2023 Series C Preferred Stock common stock dividend (note 7) 173 362 Non-cash issue costs (note 7) — 289 Equipment additions reclassified from prepaid expenses — 447 Income taxes paid — — Interest paid — —

Financial instruments (Tables)

Financial instruments (Tables)	9 Months Ended
Financial instruments (Tables)	Mar. 31, 2024
Investments, All Other Investments [Abstract]
Schedule of Assets and Liabilities Classified , Changes in the Observability of Valuation Inputs Measured using Level 3 Inputs	As of March 31, 2024, the Company’s milestone payment liability was measured using level 3 inputs. The milestone payment liability relates to contingent milestone payments for the REM-001 program that was acquired in the Adgero merger (note 1). March 31, 2024 Liability Level 1 Level 2 Level 3 Milestone payment liability — — 183 $ Balance – June 30, 2023 166 Change in fair value estimate 17 Balance – March 31, 2024 183

Nature of Operations, Corpora_2

Nature of Operations, Corporate History, and Going Concern and Management Plans - Additional Information (Detail) - USD ($) $ in Thousands			3 Months Ended		5 Months Ended	9 Months Ended
	Jun. 28, 2023	Aug. 02, 2022	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2023
Net loss			$ (2,011)	$ (3,264)		$ (5,996)	$ (11,314)
Negative cash flow from operations						(5,734)	$ (10,357)
Cash and cash equivalents			6,351		$ 6,351	6,351		$ 1,535
Accumulated deficit			$ (157,550)		$ (157,550)	$ (157,550)		$ (151,375)
Stock issued during period shares new issues		662,000
Net proceeds available under the stock purchase agreement		$ 2,008
Description of grant funding received						In addition, on June 28, 2023, the Company announced that it had been awarded approximately $2,000 in grant funding to be received over a two-year period for its REM-001 project.
Proceeds from grant funding	$ 2,000
Substantial Doubt about Companys Ability to Continues Going Concern Period						1 year
ATM Facility [Member]
Number of shares issued in transaction					53,151,000	53,151,000
Sale of Stock, Consideration Received on Transaction					$ 10,471	$ 10,471

Significant Accounting Polici_3

Significant Accounting Policies - Additional Information (Detail)		9 Months Ended
	Nov. 10, 2022 shares	Mar. 31, 2024 shares	Mar. 31, 2023 shares
Reverse stock split	50
Reverse stock split, description		As a result of the Reverse Stock Split, every 50 shares of issued and outstanding common stock were converted into one share of common stock with a proportionate reduction in the Company's authorized shares of common stock.
Reverse stock split, shares	50
Restricted Stock Units [Member]
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding		66,000	18,000
Series C Preferred Share Warrants [Member]
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding		42,000	42,000
Series C Convertible Preferred Shares [Member]
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding		235,000	245,000
Stock options [Member]
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding		222,000	198,000
Warrant [Member]
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding		693,000	713,000

Clinical Trial Deposit - Additi

Clinical Trial Deposit - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Clinical Trial Deposit [Line Items]
Patient enrollment milestones, payments (recovery)	$ (512)	$ 1,075	$ 563	$ 3,990
Deposits payments			1,075
Clinical trial deposit payments			196
Contract Research Organization Termination Cost			$ 1,000

Clinical Trials Grant - Additio

Clinical Trials Grant - Additional Information (Detail)		3 Months Ended		9 Months Ended
Clinical Trials Grant - Additional Information (Detail)	Jul. 01, 2023 USD ($) Tranches	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Proceeds from award grants	$ 2,000,000
Number of tranches \| Tranches	2
Research and Development [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Proceeds from award grants		$ 194,000	$ 0	$ 404,000	$ 0
Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Proceeds from award grants	$ 1,250,000
Tranche Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Proceeds from award grants	$ 750,000

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Beginning Balance	$ 709
Additions	20
Depreciation	(38)	$ (45)
Ending Balance	$ 691

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Capitalized cost of property and equipment	$ 879		$ 859
Capitalized cost of property and equipment not in use	599
Depreciation expense	$ 38	$ 45

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Feb. 13, 2024	Jun. 30, 2023
Preferred stock, par value		$ 0.001		$ 0.001			$ 0.001
Dividends payable				$ 6	$ 6
Valent Assignment Agreement [Member]
Percentage of net sales						5%
Related Party
Related party payables		$ 98		$ 98			$ 298
Preferred Stock Series A
Preferred Stock, shares issued		279,000		279,000			279,000
Preferred stock, rate of dividend	3%
Valent Technologies LLC [Member]
Loan payable outstanding amount	$ 279
Aggregate accrued interest	$ 29
Dividends payable		$ 2	$ 2	$ 6	$ 6
Valent Technologies LLC [Member] \| Preferred Stock Series A
Preferred Stock, shares issued	279
Preferred stock, par value	$ 1

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Issuance of Series C Preferred Stock (Detail) - Series C Preferred Stock $ in Thousands	9 Months Ended
	Mar. 31, 2024 USD ($) shares
Class Of Stock [Line Items]
Beginning Balance \| $	$ 10,366
Beginning Balance, shares \| shares	14,208
Conversion of series C preferred stock to common stock, shares \| shares	(540)
Conversion of Series C Preferred stock to common stock \| $	$ (393)
Ending Balance \| $	$ 9,973
Ending Balance, shares \| shares	13,668

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)							1 Months Ended		3 Months Ended			5 Months Ended	9 Months Ended
	Dec. 18, 2023	Sep. 19, 2023	Aug. 19, 2023	Aug. 19, 2022	Aug. 02, 2022	Aug. 19, 2021	Aug. 31, 2020	Sep. 30, 2014	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2023
Class Of Stock [Line Items]
Preferred stock, par value									$ 0.001			$ 0.001	$ 0.001		$ 0.001
Stock issued during period shares new issues					662,000
Net proceeds					$ 2,008,000
Common stock, shares issued									55,305,000			55,305,000	55,305,000		1,692,000
Issuance of restricted stock units													89,000
Stock option exercise price													$ 32.92
Number of stock options outstanding									222,000			222,000	222,000
Weighted average contractual term													8 years 9 months 3 days	9 years 10 days
Total expense for restricted stock units issuance													$ 136,000	$ 164,000
Stock-based compensation expense									$ 156,000		$ 290,000		$ 481,000	1,244,000
2017 Omnibus Incentive Plan [Member]
Class Of Stock [Line Items]
Common stock, shares issued									440,000			440,000	440,000
Percentage of fully diluted shares of common stock													8%
Two Thousand And Seventeen Omnibus Incentive Plan
Class Of Stock [Line Items]
Stock option vesting description													All of the options to purchase shares of common stock granted have a 10-year term and are subject to cancellation upon the grantees’ termination of service for the Company, with certain exceptions.
Stock option term													10 years
Stock options [Member]
Class Of Stock [Line Items]
Risk-free interest rate													4.24%
Expected term													6 years 29 days
Volatility rate													91.40%
Issuance of restricted stock units													89,000
Number of stock options outstanding									222,000			222,000	222,000		198,000
Stock options exercise price									$ 4.655			$ 4.655	$ 4.655
Aggregate intrinsic value of stock options exercisable									$ 0		$ 0	$ 0	$ 0	0
Unrecognized compensation expense									447,000			447,000	$ 447,000
Unrecognized compensation expense, term													2 years 2 months 12 days
Aggregate intrinsic value of unvested stock options													$ 0	0
Stock options [Member] \| Tranche One [Member]
Class Of Stock [Line Items]
Stock option commencing date, description													The 26 options granted to non-employee directors vest pro rata monthly over 12 months commencing on March 31, 2024.
Issuance of restricted stock units													26,000
Stock options [Member] \| Tranche Two [Member]
Class Of Stock [Line Items]
Issuance of restricted stock units													63,000
Vesting rights, percentage													25%
Restricted Stock Units [Member]
Class Of Stock [Line Items]
Stock issued during period shares new issues													4,000
Issuance of restricted stock units													0
Stock-based compensation expense													$ 136,000	54,000
Series C Preferred Stock
Class Of Stock [Line Items]
Dividends, Preferred Stock			$ 49,000
Sale of Stock, Price Per Share			$ 3.53
Preferred stock			$ 173,000						9,973,000			9,973,000	9,973,000		$ 10,366,000
Liquidation value									$ 9,973,000			$ 9,973,000	$ 9,973,000		$ 10,366,000
Preferred Stock, shares issued									14,000			14,000	14,000		14,000
Number									13,668,000			13,668,000	13,668,000
Series C-1 Preferred Shares [Member]
Class Of Stock [Line Items]
Conversion price									$ 58			$ 58	$ 58
Number									10,925,000			10,925,000	10,925,000
Series C-2 Preferred Shares [Member]
Class Of Stock [Line Items]
Conversion price									$ 60.7			$ 60.7	$ 60.7
Number									898,000			898,000	898,000
Series C-3 Preferred Shares
Class Of Stock [Line Items]
Conversion price									$ 57.5			$ 57.5	$ 57.5
Number									1,845,000			1,845,000	1,845,000
Preferred Stock Series A
Class Of Stock [Line Items]
Preferred stock									$ 279,000			$ 279,000	$ 279,000		$ 279,000
Liquidation value									$ 279,000			$ 279,000	$ 279,000		$ 279,000
Preferred stock, rate of dividend								3%
Preferred Stock, shares issued									279,000			279,000	279,000		279,000
Change in preferred stock													$ 0	0
Preferred Stock Series A \| Exchange Agreement [Member]
Class Of Stock [Line Items]
Preferred stock, rate of dividend								3%
Preferred Stock, shares issued								279,000
Preferred stock, par value								$ 1
Private Placement [Member] \| Series C Preferred Stock Warrants
Class Of Stock [Line Items]
Shares issued of common stock for services													2,504
Shares issued, price per share									$ 1,000			$ 1,000	$ 1,000
ATM Facility [Member]
Class Of Stock [Line Items]
Sale of Stock, Price Per Share									$ 0.21			$ 0.21	$ 0.21
Share issuance costs												$ 435,000
Amount of purchase common stock issued									$ 7,892,000	$ 2,579,000
Aggregate number of shares sell												53,151,000	53,151,000
Sales agreement aggregate offering price	$ 10,900,000	$ 2,850,000
Net proceeds												$ 10,471,000	$ 10,471,000
ATM Facility [Member] \| Sales Agreement [Member]
Class Of Stock [Line Items]
Commission rate		3%
Lincoln Park [Member]
Class Of Stock [Line Items]
Sale of Stock, Price Per Share									$ 0.23			$ 0.23	$ 0.23
Aggregate number of shares sell													400,000
Net proceeds													$ 105,000
Merger Agreement [Member] \| Series C Preferred Stock \| First Anniversary [Member]
Class Of Stock [Line Items]
Common stock dividends percentage						10%
Merger Agreement [Member] \| Series C Preferred Stock \| Second Anniversary [Member]
Class Of Stock [Line Items]
Common stock dividends percentage				15%
Merger Agreement [Member] \| Series C Preferred Stock \| Third Anniversary [Member]
Class Of Stock [Line Items]
Common stock dividends percentage			20%
Merger Agreement [Member] \| Private Placement [Member] \| Series C Preferred Stock
Class Of Stock [Line Items]
Shares issued of common stock for services							25,028,000
Shares issued, price per share							$ 1,000
Merger Agreement [Member] \| Private Placement [Member] \| Series C Preferred Stock \| First Anniversary [Member]
Class Of Stock [Line Items]
Common stock dividends percentage													10%
Merger Agreement [Member] \| Private Placement [Member] \| Series C Preferred Stock \| Second Anniversary [Member]
Class Of Stock [Line Items]
Common stock dividends percentage													15%
Merger Agreement [Member] \| Private Placement [Member] \| Series C Preferred Stock \| Third Anniversary [Member]
Class Of Stock [Line Items]
Common stock dividends percentage													20%
Merger Agreement [Member] \| Private Placement [Member] \| Series C Preferred Stock \| Fourth Anniversary [Member]
Class Of Stock [Line Items]
Common stock dividends percentage													25%
Purchase Agreement [Member]
Class Of Stock [Line Items]
Stock issued during period shares new issues					33,000
Maximum committed purchase obligation					$ 2,000,000
Percentage of aggregate number of shares sell													20%
Net proceeds														$ 1,860,000
Common stock, shares issued											229,000			229,000
Purchase Agreement [Member] \| Regular Purchase [Member]
Class Of Stock [Line Items]
Stock issued during period shares new issues					10,000
Purchase Agreement [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Amount of purchase common stock issued					$ 20,000,000

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Series C Preferred Stock Outstanding, Conversion Shares and Aggregate Dividends (Detail) shares in Thousands	9 Months Ended
	Mar. 31, 2024 $ / shares shares
Series C-1 Preferred Shares [Member]
Class Of Stock [Line Items]
Number	10,925
Conversion price \| $ / shares	$ 58
Number of conversion shares (in thousands)	188
Dividend Shares (in thousands)	151
Series C-2 Preferred Shares [Member]
Class Of Stock [Line Items]
Number	898
Conversion price \| $ / shares	$ 60.7
Number of conversion shares (in thousands)	15
Dividend Shares (in thousands)	10
Series C-3 Preferred Shares
Class Of Stock [Line Items]
Number	1,845
Conversion price \| $ / shares	$ 57.5
Number of conversion shares (in thousands)	32
Dividend Shares (in thousands)	24
Series C Preferred Stock
Class Of Stock [Line Items]
Number	13,668
Number of conversion shares (in thousands)	235
Dividend Shares (in thousands)	185
Series C Preferred Stock \| 10% - August 19, 2021 [Member]
Class Of Stock [Line Items]
Dividend Shares (in thousands)	34
Series C Preferred Stock \| 15% - August 19, 2022 [Member]
Class Of Stock [Line Items]
Dividend Shares (in thousands)	43
Series C Preferred Stock \| 20% - August 19, 2023 [Member]
Class Of Stock [Line Items]
Dividend Shares (in thousands)	49
Series C Preferred Stock \| 25% - August 19, 2024 [Member]
Class Of Stock [Line Items]
Dividend Shares (in thousands)	59

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Aggregate Information on all Equity Compensation Plans (Details) shares in Thousands	9 Months Ended
	Mar. 31, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares of common stock to be issued upon exercise of outstanding stock options and rights	222
Weighted-average exercise price of stock options and rights \| $ / shares	$ 32.92
Number of shares of common stock remaining available for future issuance under equity compensation plans	144
Equity Compensation Plans Approved by Security Holders - 2017 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares of common stock to be issued upon exercise of outstanding stock options and rights	222
Weighted-average exercise price of stock options and rights \| $ / shares	$ 21.4
Number of shares of common stock remaining available for future issuance under equity compensation plans	144
Equity Compensation Plans Not Approved by Security Holders - Del Mar (BC) 2013 Amended and Restated Stock Option Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares of common stock to be issued upon exercise of outstanding stock options and rights	0
Weighted-average exercise price of stock options and rights \| $ / shares	$ 2,060.08

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Aggregate Information on all Equity Compensation Plans (Parenthetical) (Details) shares in Thousands	Mar. 31, 2024 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares of common stock remaining available for future issuance under equity compensation plans	144
Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares of common stock remaining available for future issuance under equity compensation plans	144

Stockholders' Equity - Schedu_3

Stockholders' Equity - Schedule of Outstanding Under the Legacy Plan (Detail)	9 Months Ended
	Mar. 31, 2024 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	89,000
Ending balance	222,000
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance	198,000
Granted	89,000
Expired	(34,000)
Forfeited	(31,000)
Ending balance	222,000
Beginning balance \| $ / shares	$ 51.71
Granted \| $ / shares	4.66
Expired \| $ / shares	107.69
Forfeited \| $ / shares	8.26
Ending balance \| $ / shares	$ 30.70

Stockholders' Equity - Summar_3

Stockholders' Equity - Summary of Stock Options Outstanding and Exercisable (Detail)	9 Months Ended
	Mar. 31, 2024 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding	222,000
Stock options exercisable	102,000
Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price \| $ / shares	$ 4.66
Number of stock options outstanding	79,000
Weighted average remaining contractual life (years)	9 years 5 months 1 day
Stock options exercisable	15,000
Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price \| $ / shares	$ 6.04
Number of stock options outstanding	9,000
Weighted average remaining contractual life (years)	8 years 10 months 20 days
Stock options exercisable	2,000
Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price \| $ / shares	$ 8.79
Number of stock options outstanding	34,000
Weighted average remaining contractual life (years)	8 years 4 months 2 days
Stock options exercisable	14,000
Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding	6,000
Weighted average remaining contractual life (years)	8 years 6 months 10 days
Stock options exercisable	6,000
Exercise Price Four [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price \| $ / shares	$ 12.75
Exercise Price Four [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price \| $ / shares	$ 16.25
Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding	73,000
Weighted average remaining contractual life (years)	7 years 6 months 21 days
Stock options exercisable	44,000
Exercise Price Five [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price \| $ / shares	$ 30.5
Exercise Price Five [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price \| $ / shares	$ 48
Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding	13,000
Weighted average remaining contractual life (years)	7 years 21 days
Stock options exercisable	13,000
Exercise Price Six [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price \| $ / shares	$ 62
Exercise Price Six [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price \| $ / shares	68.5
Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price \| $ / shares	$ 85
Number of stock options outstanding	7,000
Weighted average remaining contractual life (years)	6 years 5 months 15 days
Stock options exercisable	7,000
Exercise Price Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding	1,000
Weighted average remaining contractual life (years)	2 years 1 month 9 days
Stock options exercisable	1,000
Exercise Price Eight [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price \| $ / shares	$ 304.95
Exercise Price Eight [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price \| $ / shares	$ 2,660

Stockholders' Equity - Schedu_4

Stockholders' Equity - Schedule of Valuation Assumptions Using a Black-Scholes Pricing Model (Detail) - Stock options [Member]	9 Months Ended
	Mar. 31, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility rate	91.40%
Risk-free interest rate	4.24%
Expected term	6 years 29 days

Stockholders' Equity - Schedu_5

Stockholders' Equity - Schedule of Stock Option Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 156	$ 290	$ 481	$ 1,244
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	50	94	143	368
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 106	$ 196	$ 338	$ 876

Stockholders' Equity - Schedu_6

Stockholders' Equity - Schedule of Unvested Stock Options (Detail)	9 Months Ended
	Mar. 31, 2024 $ / shares shares
Equity [Abstract]
Beginning balance \| shares	118,000
Granted \| shares	89,000
Vesting of restricted stock units \| shares	(56,000)
Forfeiture of restricted stock units \| shares	(31,000)
Ending balance \| shares	120,000
Beginning balance \| $ / shares	$ 24.12
Granted \| $ / shares	4.66
Vested \| $ / shares	19.31
Forfeited \| $ / shares	8.26
Ending balance \| $ / shares	$ 16.07

Stockholders' Equity - Schedu_7

Stockholders' Equity - Schedule of Restricted Stock Units (Details)	9 Months Ended
	Mar. 31, 2024 shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance	118,000
Issuance of restricted stock units	89,000
Vesting of restricted stock units	(56,000)
Forfeiture of restricted stock units	(31,000)
Ending balance	120,000
Restricted Stock Units [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance	78,000
Issuance of restricted stock units	0
Vesting of restricted stock units	(4,000)
Forfeiture of restricted stock units	(8,000)
Ending balance	66,000

Stockholders' Equity - Schedu_8

Stockholders' Equity - Schedule of Warrants (Detail)	9 Months Ended
Stockholders' Equity - Schedule of Warrants (Detail)	Mar. 31, 2024 $ / shares shares
Stock option exercise price	$ 32.92
Common Stock Warrants [Member]
Balance - June 30, 2023 \| shares	713,000
Balance - March 31, 2024 \| shares	693,000
Beginning balance	$ 43.55
Ending balance	$ 43.12
Common Stock Warrants [Member] \| Issued For Services One [Member]
Expiry of warrants \| shares	(20,000)
Expired	$ 57.14

Stockholders' Equity - Schedu_9

Stockholders' Equity - Schedule of Outstanding Warrants (Detail) - Warrant [Member]	9 Months Ended
	Mar. 31, 2024 $ / shares shares
Number	693,000
Investor [Member]
Number	325,000
Warrants exercise price \| $ / shares	$ 20.50
Expiry date	Apr. 14, 2027
InvestorOne [Member]
Number	240,000
Warrants exercise price \| $ / shares	$ 62.50
Expiry date	Mar. 28, 2025
InvestorTwo [Member]
Number	65,000
Warrants exercise price \| $ / shares	$ 50
Expiry date	Aug. 16, 2024
Investor Three [Member]
Number	15,000
Warrants exercise price \| $ / shares	$ 155
Expiry date	Jun. 05, 2024
NBTS [Member]
Number	3,000
Warrants exercise price \| $ / shares	$ 54.50
Expiry date	Jun. 19, 2025
Agent [Member]
Number	32,000
Warrants exercise price \| $ / shares	$ 33.12
Expiry date	Oct. 14, 2026
Agent One [Member]
Number	12,000
Warrants exercise price \| $ / shares	$ 78.12
Expiry date	Mar. 28, 2025
Agent Two [Member]
Number	1,000
Warrants exercise price \| $ / shares	$ 193.75
Expiry date	Jun. 03, 2024

Stockholders' Equity - Sched_10

Stockholders' Equity - Schedule of Outstanding Series C Preferred Stock Warrants (Detail) - Series C Warrants	9 Months Ended
	Mar. 31, 2024 Warrant $ / shares shares
Balance	2,444
Number of Warrants Issued \| Warrant	0
Number of Warrants Exercised	0
Balance	2,444
Preferred Series C-1 Agent Warrants [Member]
Balance	1,929
Number of Warrants Issued \| Warrant	0
Number of Warrants Exercised	0
Balance	1,929
Warrants exercise price \| $ / shares	$ 58
Preferred Series C-2 Agent Warrants [Member]
Balance	219
Number of Warrants Issued \| Warrant	0
Number of Warrants Exercised	0
Balance	219
Warrants exercise price \| $ / shares	$ 60.70
Preferred Series C-3 Agent Warrants [Member]
Balance	296
Number of Warrants Issued \| Warrant	0
Number of Warrants Exercised	0
Balance	296
Warrants exercise price \| $ / shares	$ 57.50

Stockholders' Equity - Sched_11

Stockholders' Equity - Schedule of Outstanding Series C Agent Warrants (Detail) - Series C Warrants - $ / shares	9 Months Ended
	Mar. 31, 2024	Jun. 30, 2023
Number	2,444	2,444
Number of conversion shares (in thousands)	42,000
Cumulative common stock dividends	30,000
Series 1 Warrants Outstanding
Number	1,929
Warrants exercise price	$ 58
Number of conversion shares (in thousands)	33,000
Cumulative common stock dividends	23,000
Series 2 Warrants Outstanding Member
Number	219
Warrants exercise price	$ 60.70
Number of conversion shares (in thousands)	4,000
Cumulative common stock dividends	3,000
Series 3 Warrants Outstanding
Number	296
Warrants exercise price	$ 57.50
Number of conversion shares (in thousands)	5,000
Cumulative common stock dividends	4,000

Supplementary Statement of Ca_3

Supplementary Statement of Cash Flows Information - Schedule of Supplementary Statement of Cash Flows Information (Detail) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Supplemental Cash Flow Elements [Abstract]
Non-cash issue costs (note 7)		$ 289
Equipment additions reclassified from prepaid expenses		447
Preferred Stock Series C
Supplemental Cash Flow Elements [Abstract]
Preferred Stock common stock dividend (note 7)	$ 173	$ 362

Financial instruments -Schedule

Financial instruments -Schedule of Assets and Liabilities Classified , Changes in the Observability of Valuation Inputs Measured using Level 3 Inputs (Details) $ in Thousands	9 Months Ended
	Mar. 31, 2024 USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Balance	$ 166
Change in fair value estimate	17
Balance	183
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Milestone payment liability	$ 183

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) $ / shares in Units, $ in Thousands		9 Months Ended
	Apr. 02, 2024 USD ($) Patients $ / shares	Mar. 31, 2024 $ / shares	Jun. 30, 2023 $ / shares
Subsequent Event [Line Items]
Common stock, par value \| $ / shares		$ 0.001	$ 0.001
TuHURA Biosciences, Inc. [Member]
Subsequent Event [Line Items]
Description of contingent value rights		Existing Company stockholders will receive contingent value rights (“CVR”), entitling them to receive shares of the Company's common stock upon achievement of enrollment of a minimum of 10 patients in the REM-001 clinical trial, with such patients each completing 8 weeks of follow-up on or before December 31, 2025.
Subsequent Event [Member] \| Chief Executive Officer [Member]
Subsequent Event [Line Items]
One-time special bonus	$ 327
Subsequent Event [Member] \| TuHURA Biosciences, Inc. [Member]
Subsequent Event [Line Items]
Common stock, par value \| $ / shares	$ 0.001
Minimum of number of patients enrolled \| Patients	10
Percentage of shares expected to collectively owned by stockholders under post merger	2.85%
Percentage of shares underlying CVR under post merger	5.45%
Percentage of shares expected to collectively owned	97.15%
Percentage of shares underlying the CVR	94.55%
Termination fees payable	$ 1,000
Accrued fees	93
Subsequent Event [Member] \| TuHURA Biosciences, Inc. [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Expenses incurred in connection with the merger agreement	$ 750